News

 

 

Clinical Trials - April 2013

Marc Ernstoff
Professor
Immunology and Cancer Immunotherapy

  • Bristol Myers Squibb
    A multi-site retrospective observational study of US patients with unresectable or metastatic melanoma receiving Ipilimumab (Yervoy®) as first-line therapy